Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS‐mutant and wild‐type melanoma

Publisher: John Wiley & Sons Inc

E-ISSN: 1755-148x|31|1|110-114

ISSN: 1755-1471

Source: PIGMENT CELL & MELANOMA RESEARCH, Vol.31, Iss.1, 2018-01, pp. : 110-114

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract